Related references
Note: Only part of the references are listed.Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations
R. Donald Harvey et al.
CLINICAL CANCER RESEARCH (2021)
Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom
Andrea V. Margulis et al.
EPIDEMIOLOGY (2018)
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
S. Novello et al.
ANNALS OF ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer
Shin Hye Yoo et al.
THORACIC CANCER (2018)
Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
K. Al-Baimani et al.
CURRENT ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparison of cancer diagnosis recording between the Clinical Practice Research Datalink, Cancer Registry and Hospital Episodes Statistics
Chanpreet S. Arhi et al.
CANCER EPIDEMIOLOGY (2018)
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
Christine M. Cramer-van der Welle et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
Marco Donia et al.
EUROPEAN JOURNAL OF CANCER (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?
Shaun Treweek et al.
EUROPEAN JOURNAL OF CANCER (2015)
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Emily Herrett et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
D. Y. C. Heng et al.
ANNALS OF ONCOLOGY (2014)
Smoking and Long-Term Risk of Type 2 Diabetes: The EPIC-InterAct Study in European Populations
Annemieke M. W. Spijkerman et al.
DIABETES CARE (2014)
Comorbidities in lung cancer: prevalence, severity and links with socioeconomic status and treatment
Derek Grose et al.
POSTGRADUATE MEDICAL JOURNAL (2014)
Cancer recording and mortality in the General Practice Research Database and linked cancer registries
Rachael Boggon et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial
Akira Ueda et al.
ONCOTARGETS AND THERAPY (2013)
Clinical pharmacology considerations in biologics development
Liang Zhao et al.
ACTA PHARMACOLOGICA SINICA (2012)
The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials
J. Clarey et al.
ANNALS OF ONCOLOGY (2012)
Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England. Population-based cohort study
A. Dregan et al.
CANCER EPIDEMIOLOGY (2012)
Chronic obstructive pulmonary disease
Marc Decramer et al.
LANCET (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
Janette Vardy et al.
BMC CANCER (2009)
The problem of tobacco smoking
R Edwards
BRITISH MEDICAL JOURNAL (2004)
Epidemiology of smoking-induced cardiovascular disease
DM Burns
PROGRESS IN CARDIOVASCULAR DISEASES (2003)
Share Paper
